CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

OBJECTIVE—: Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis. In clinical trials, anacetrapib, a CETP (cholesteryl ester transfer protein) inhibitor, causes significant redu...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Tiffany, Zhou, Haihong, Karmally, Wahida, Ramakrishnan, Rajasekhar, Holleran, Stephen, Liu, Yang, Jumes, Patricia, Wagner, John A., Hubbard, Brian, Previs, Stephen F., Roddy, Thomas, Johnson-Levonas, Amy O., Gutstein, David E., Marcovina, Santica M., Rader, Daniel J., Ginsberg, Henry N., Millar, John S., Reyes-Soffer, Gissette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Clinical and Population Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567403/
https://www.ncbi.nlm.nih.gov/pubmed/28729361
http://dx.doi.org/10.1161/ATVBAHA.117.309549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567403/
https://www.ncbi.nlm.nih.gov/pubmed/28729361
http://dx.doi.org/10.1161/ATVBAHA.117.309549

Ejemplares similares